 For this, the investigators capitalize on their previous melanoma clinical trial published by Zajac P et al in Human Gene Ther 2003 and take advantage of a proprietary recombinant vaccinia virus replication inactivated expressing 5 minigenes: 3 melanoma associated antigens and 2 costimulatory molecules. Immunization with the recombinant vaccinia virus is followed by 3 boosts with soluble, synthetic melanoma associated antigens. 